ZLAB · Zai Lab Limited

Current Thesis

The leg being bought is a re-rating from "China in-licensing distributor" to global originator, and the asset carrying it is zocilurtatug pelitecan (zoci, formerly ZL-1310), Zai Lab's internally discovered DLL3-targeted ADC. The Q2 2026 report (2026-08-06) showed the commercial base doing its job and nothing more — total revenue $106.3M against $110.0M in Q2 2025, net product revenue $105.8M against $109.1M, up 11% sequentially — while R&D rose to $61.8M from $50.6M a year earlier and the net loss widened to $50.8M from $40.7M. What moved the shares 52.6% over three months is not that P&L; it is zoci: a 54% intracranial response rate in SCLC brain metastases presented at AACR 2026, a 38% ORR with roughly 56% disease control in extrapulmonary neuroendocrine carcinomas, an FDA orphan-drug designation in neuroendocrine carcinomas granted 2026-08-03, and Citigroup's 2026-08-07 reiterated Buy with the target raised to $45. The narrative is accelerating — each of those attention events is dated inside the last five months, the sell-side target sits well above the 2026-08-28 close of $26.08, and the dataset that most matters (first-line ES-SCLC combination Phase 1) has not been shown yet, arriving at ESMO in Madrid on 2026-10-23 to 2026-10-27.

Bullish and bearish views on Zai Lab Limited

The model's bull view on Zai Lab Limited (ZLAB), in brief: Zoci Phase 1 in second-line-plus ES-SCLC produced a 54% response rate in brain metastases (AACR 2026 investor presentation), a setting where systemic ADCs historically underperform; in extrapulmonary NECs the reported figures were a 38% ORR and ~56% disease control. The bear view: Revenue is shrinking year over year: total revenue -3% (to $106.3M from $110.0M) and net product revenue -3% (to $105.8M from $109.1M) in Q2 2026. Both cases follow in full.

Bull Case

• Zoci Phase 1 in second-line-plus ES-SCLC produced a 54% response rate in brain metastases (AACR 2026 investor presentation), a setting where systemic ADCs historically underperform; in extrapulmonary NECs the reported figures were a 38% ORR and ~56% disease control.
• FDA granted orphan-drug designation to zoci for neuroendocrine carcinomas on 2026-08-03 — a regulatory acknowledgement of the epNEC expansion the company said (Q2 release) it will advance to registrational development in H2 2026.
• The global Phase 3 DLLEVATE study in second-line ES-SCLC is enrolling, with enrollment completion guided to H1 2027 and a potential accelerated-approval BLA in 2027; management framed a first U.S. product launch as possible in 2028.
• Commercial base funds the pivot without an immediate financing need on the reported numbers: cash and equivalents $607.5M plus $10.0M short-term investments plus $100.0M restricted cash, $717.5M total as of 2026-06-30, against an adjusted loss from operations of $60.4M in Q2.
• KarXT launched in mainland China in June 2026 — the first new mechanism of action in schizophrenia in over 70 years, per management — with NRDL inclusion sought for 2027; VYVGART volumes grew double digits sequentially in Q2.

• Citigroup maintained Buy and raised its target to $45 on 2026-08-07, the day after the print.

Bear Case

• Revenue is shrinking year over year: total revenue -3% (to $106.3M from $110.0M) and net product revenue -3% (to $105.8M from $109.1M) in Q2 2026. The company guides only to "stabilization" in H2 2026 and defers "meaningful growth" to 2027.
• Management declined on the Q2 call to reinstate a specific profitability timeline, after previously carrying one; the claim retained is narrower — that the business remains "commercially profitable," which is a segment-level statement, not a net result. The net loss was $50.8M.
• Operating cost is going the wrong way while revenue is flat: R&D $61.8M (from $50.6M) and SG&A $72.9M (from $71.0M) in Q2 2026.
• The zoci case rests on Phase 1 data; management described the ESMO dataset as roughly 60 patients at 8–9 months median follow-up. Response rates in small single-arm cohorts routinely compress in randomized settings, and DLL3 in SCLC already has an approved competitor in Amgen's tarlatamab.
• Partner pipeline has failed before: Amgen stopped the FORTITUDE-102 first-line gastric study of bemarituzumab in November 2025, removing a China opportunity Zai Lab had carried.
• China pricing is a structural drag — NRDL inclusion, sought for KarXT and VYVGART Hytrulo in 2027, buys volume by cutting price.
• Nothing in the reported revenue is U.S.-sourced, and management's own framing puts the first U.S. launch no earlier than 2028; the valuation leg is therefore a 2028 asset discounted through a 2026 tape.

Setup & Price Structure

• The 2026-08-28 close was $26.08, 24.3% below the $34.44 52-week high, after a three-month price change of +52.6%. The advance has recovered ground rather than made a new high, so the $34.44 level stands as unworked overhead supply.
• RSI(14) at 65.0 on 2026-08-28 is firm without being extended; the momentum reading has not reached the zone where prior legs in this name have stalled on exhaustion alone.
• Crowding observables, stated as observed: a sell-side target of $45 (Citigroup, 2026-08-07) sits far above the last close; the 30-day window contains no company earnings date, so there is no scheduled print to compress positioning into; and no insider Form 4 sales or equity issuance appear in the filings and news reviewed for this note through 2026-08-28. Absence of an issuance is consistent with the $717.5M liquidity position, not evidence about intent.
• Structurally, the leg is defined by what happens at ESMO between 2026-10-23 and 2026-10-27. Between now and then the name trades on flow and China-biotech beta rather than company data, which is the part of this setup with no company-side support underneath it.

Catalyst Calendar (next 30 days)

• 2026-08-30 to 2026-09-29: no company-dated event. This is the honest state of the window — every zoci milestone the company published sits in October or later.
• ~2026-09-30 (est.) — argenx topline from the ALKIVIA myositis registrational study, guided by Zai Lab (Q2 release) to Q3 2026. Zai Lab participates in Greater China; the date is a quarter boundary, not a confirmed calendar date.
• ~2026-09-30 (est.) — elegrobart thyroid-eye-disease enrollment completion, guided to Q3 2026; topline is 2027.
• H2 2026, undated — ZL-1503 (IL-13/IL-31Rα) first-in-human single-ascending-dose PK/PD data.
• Outside the window but dated and load-bearing: 2026-10-23 to 2026-10-27 ESMO Congress, Madrid (zoci first-line ES-SCLC Phase 1 data); ~2026-11-05 (est.) Q3 2026 print; 2026-11-30 Vertex povetacicept PDUFA in IgAN; by 2026-12-31 ZL-1311 IND submission and the decision on initiating the first-line ES-SCLC registrational Phase 3.

What Would Change Our Mind

The break comes from the data first. An ESMO first-line dataset that lands materially below the second-line Phase 1 numbers already published — or a passage of the 2026-10-27 conference close without the company committing to the first-line registrational Phase 3 it said in the Q2 release it would start in H2 2026 "subject to data" — removes the reason the shares are 52.6% higher over three months. A second, slower break is commercial: a Q3 print in early November showing product revenue below the $105.8M reported for Q2, which would contradict the stabilization guide and push the growth story past 2027. On price, a weekly close below $22 would surrender most of the three-month advance and leave the shares roughly 36% under the $34.44 52-week high, which is the condition that reads as the re-rating being unwound rather than digested. In the other direction, a weekly close above $34.44 on the ESMO data would confirm the base has been taken out rather than merely retraced.

Correlation Notes

• The ADS is one leg of a dual listing; the ordinary shares trade in Hong Kong (9688.HK) and the Asian session sets the overnight mark before the US open.
• Partner news transmits directly into this name: argenx (VYVGART/efgartigimod), Vertex (povetacicept), Bristol Myers Squibb (KarXT/Cobenfy) and Amgen (bemarituzumab, and separately tarlatamab as the approved DLL3 competitor). A readout at any of those companies is a Zai Lab datapoint with no Zai Lab press release attached.
• Within oncology, zoci is priced against the DLL3 field generally; competitor data in SCLC brain metastases is the most direct comparison set for the ESMO presentation.
• As a US-listed China-operating biopharma, the shares carry the China-ADR policy discount alongside the ordinary biotech rate sensitivity, so drawdowns can arrive from headlines that never mention the company.